Hengrui Pharmaceuticals reports new BCL6 degradation inducers

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new BCL6 degradation inducers potentially useful for the treatment of autoimmune disease and cancer.